Effect of calcium channel antagonists nifedipine and nicardipine on rat cytochrome P-450 2B and 3A forms

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1436-1441

  Zangar, Richard C ^a   Okita, Janice Rice ^b   Kim, Hyesook ^c   Thomas, Paul E ^d   Anderson, Alan ^f   Edwards, Robert J ^e   Springer, David L ^a   Okita, Richard T ^b  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^f 105 Wegner Hall ^*

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CYTOCHROME P450; DILTIAZEM; ISOENZYME; NICARDIPINE; NIFEDIPINE;

ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; IMMUNOBLOTTING; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ISOENZYMES; LIVER; MALE; NICARDIPINE; NIFEDIPINE; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY; STEROID HYDROXYLASES;

EID: 0032768127     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
2. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T and Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochrome P-450. Biochem Pharmacol 34:3337-3345.
3. Cheesman MJ and Reilly PEB (1998) Differential inducibility of specific mRNA corresponding to five CYP3A isoforms in female rat liver by RU486 and food deprivation. Comparison with protein abundance and enzymic activities. Biochem Pharmacol 56:473-481.
4. Debri K, Boobis AR, Davies DS and Edwards RJ (1995) Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 50:2047-2056.
5. Desrochers M, Christou M, Jefcoate C, Belzil A and Anderson A (1996) New proteins in the rat CYP2B subfamily: Presence in liver microsomes of the constitutive CYP2B3 protein and the phenobarbital-inducible protein product of alternatively spliced CYP2B2 mRNA. Biochem Pharmacol 52:1311-1319.
6. Dow RJ and Graham DJM (1984) The effect of nicardipine hydrochloride, a calcium antagonist, on indices of hepatic microsomal enzyme activity in man. Br J Clin Pharmacol 18:296P-297P.
7. Dow RJ and Graham DJM (1986) A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. Br J Clin Pharmacol 22:195S-202S.
8. Guengerich FP, Brian WR, Iwasaki M, Sari M-A, Bäärnhielm C and Berntsson, P (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 34:1838-1844.
9. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
10. Higuchi S, Sasaki H, Shiobara Y and Sado T (1977) Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. Xenobiotica 7:469-479.
11. Higuchi S and Shiobara Y (1980) Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 12:889-896.
12. Huss JM, Wang SI, Astrom A, McQuiddy P and Kasper CB (1998) Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc Natl Acad Sci USA 93:4666-4670.
13. Jean A, Reiss A, Desrochers M, Dubois S, Trottier E, Trottier Y, Wirtanen L, Adesnik M, Waxman DJ and Anderson A (1994) Rat liver cytochrome P-450 2B3: Structure of the CYP2B3 gene and immunological identification of a constitutive P450 2B3-like protein in rat liver. DNA Cell Biol 13:781-792.
14. Kim EY, Krygold S, Putt DA and Kim H (1997) Induction of cytochrome P450 (CYP) 3A1, 3A2 and 3A23 after treatment with dexamethasone, pyridine, and phenobarbital: An antipeptide antibody approach. FASEB J 11:A818.
15. Kirita S and Matsubara T (1993) cDNA cloning and characterization of a novel member of steroid-induced cytochrome P450 3A in rats. Arch Biochem Biophys 307:253-258.
16. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Wilison TM, Zetterström RH, Perlmann T and Lehmann J (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
17. Koleva MR and Stoychev TS (1993) On the enzyme-inducing action of calcium antagonists. Arch Toxicol 67:294-296.
18. Koleva MR and Stoychev TS (1995) Effect of nifedipine, verapamil and diltiazem on the enzyme-inducing activity of phenobarbital and beta-naphthoflavone. Gen Pharmacol 26:225-228.
19. Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf CR and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 348:332-337.
20. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Mäenpää J, Ruskoaho H and Pelkonen O (1989) Inhibition of hepatic microsomal drug metabolism in rats by five calcium antagonists. Pharmacol Toxicol 64:446-450.
22. Murray M and Butler AM (1996) Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther 279:1447-1452.
23. Okita JR, Castle PJ and Okita RT (1993) Characterization of cytochromes P450 in liver and kidney of rats treated with di-(2-ethylhexyl)phthalate. J Biochem Toxicol 8:135-144.
24. Pichard L, Fabre I, Fabre G, Domergue J, Aubert BS, Mourad G and Maurel P (1990a) Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
25. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot J-P and Maurel P (1990b) Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 18:711-719.
26. Quattrochi LC, Yockey CB, Barwick JL and Guzelian PS (1998) Characterization of DNA-binding proteins required for glucocorticoid induction of CYP3A23. Arch Biochem Biophys 349:251-260.
27. Reik LM, Levin W, Ryan DE, Maines SL and Thomas PE (1985) Monoclonal antibodies distinguish among isozymes of the cytochrome P-450b subfamily. Arch Biochem Biophys 242:365-382.
28. Sharer JE and Wrighton SA (1996) Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 24:487-494.
29. Sorkin EM and Clissold SP (1987) Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 33:296-345.
30. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
31. Wrighton SA, Maurel P, Schuetz EG, Watkins PB, Young B and Guzelian PS (1985) Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry 24:2171-2178.
32. Zangar RC and Novak RF (1997) Effects of fatty acids and ketone bodies on cytochromes P450 2B, 4A, and 2E1 expression in primary cultured rat hepatocytes. Arch Biochem Biophys 337:217-224.
33. Zangar RC and Novak RF (1998) Posttranslational elevation of cytochrome P450 3A levels and activity by dimethyl sulfoxide. Arch Biochem Biophys 353:1-9.
34. Zangar RC, Springer DL and Buhler DR (1993) Alterations in cytochrome P-450 levels in adult rats following neonatal exposure to xenobiotics. J Toxicol Environ Health 38:43-55.
35. Zangar RC, Woodcroft KJ, Kocarek TA and Novak RF (1995) Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes. Drug Metab Dispos 23:681-687.
36. Zangar RC, Woodcroft KJ and Novak RF (1996) Differential effects of ciprofibrate on renal and hepatic cytochrome P450 2E1 expression. Toxicol Appl Pharmacol 141: 110-116.